全球开放合作的目光再次聚焦上海国家会展中心！ 今年是"十四五"规划的收官之年，也是"十五五"规划谋篇布局之年。辉瑞将以"向中国道未来"为主题亮 相第八届进博会，展现辉瑞根植中国三十六载、服务患者的坚定决心，更彰显"辉瑞中国2030战 略"与"十五五"规划建议同频共振的发展脉络。 回望 "十四五"期间，辉瑞始终与中国医药创新浪潮协同共进，持续加速创新引入，借力进博会等国际 化平台推动前沿药物快速惠及中国患者。 本届进博会期间，辉瑞将集中展示连续七年参展以来的17款"进博宝宝"，并重磅呈现"辉瑞中国2030战 略"发布一周年的关键进展，递交一份与中国共前行、同未来的周年答卷。 "进博会是中国坚定不移推进高水平对外开放的生动缩影，也是辉瑞与中国医疗健康生态深度链接、守 护患者健康的重要桥梁。"辉瑞全球高级副总裁、辉瑞中国区总裁Jean-Christophe Pointeau表示，"'十五 五'规划建议提出加快建设健康中国发展战略，将创新作为生物医药领域的核心驱动力，强调提升基层 医疗可及性、强化重大疾病防控，这与辉瑞深耕中国的长期愿景高度契合。" 他进一步指出："中国正日益成为全球创新的策源地。为更好地支持中国生物 ...

Group 1 - The introduction of a "commercial insurance innovative drug catalog" in the national medical insurance negotiation is expected to initiate a new growth cycle for innovative drugs [1] - The 2025 national medical insurance negotiation, which began on October 30, marks the 8th adjustment of the medical insurance catalog since the establishment of the National Medical Insurance Administration [1] Group 2 - The animation drama market has experienced explosive growth this year, with a compound monthly growth rate of 83% in the supply of drama titles in the first half of 2025 [1] - Over 3,000 works were produced in the first half of the year, and the market revenue scale has increased twelvefold, with expectations for the annual market size to exceed 20 billion [1]

Core Insights - The CXO (Contract Research Organization) sector in A-shares shows strong growth, with 20 out of 29 listed companies reporting year-on-year revenue increases in the first three quarters [1] - In the third quarter alone, 21 companies achieved year-on-year revenue growth, driven by international demand for innovative drugs and a supportive policy environment [2] Industry Overview - The innovative drug industry is experiencing a dual boost from policy support and surging demand, which is activating new drug research and development needs, benefiting the CXO sector [2] - The National Healthcare Security Administration and the National Health Commission issued measures to support high-quality development of innovative drugs, proposing 16 policies to enhance the entire chain of support [2] Company Performance - Several CXO companies reported robust order backlogs for the first three quarters. For instance, WuXi AppTec reported a backlog of 59.88 billion yuan, a 41.2% increase year-on-year [2] - Innosilicon reported a nearly 20% increase in order amounts compared to the end of 2024, while Haoyuan reported a 50% year-on-year increase in its small molecule business orders [3] Market Trends - The first half of the year saw a surge in Chinese innovative drugs going global, with total foreign licensing transactions reaching $60 billion, accounting for 99% of global related transactions [3] - Morgan Stanley's healthcare research head in Greater China anticipates stable long-term growth in foreign licensing transactions for Chinese innovative drugs, with multinational companies likely to be more active in acquiring Chinese assets [3] Future Outlook - The CXO industry is expected to benefit from a combination of demand recovery and structural upgrades, with policies, capital, and technology contributing to a more certain industry development [3] - The industry is transitioning from "scale dividends" to "technology premiums," with technological iteration and process innovation becoming the core of competition [3]

今年以来，主动权益基金重回舞台中央。 Wind数据显示，今年以来截至9月30日，代表主动权益类基金业绩表现的万得普通股票型基金指数、万得偏股混合型基金指数和万得灵活配置型基金指数 增长率分别达35.15%、35.37%和26.07%，均明显跑赢同期沪深300指数增长率的17.94%。 这其中，工银瑞信旗下多只基金表现突出。 根据基金托管行复核数据显示，截至9月30日，工银医药健康股票、工银健康生活混合、工银健康产业混合、工银新经济混合等4只基金年内回报均超 60%，显著超越同期业绩比较基准及沪深300指数涨幅。 工银新经济混合年内回报率高达104.57%，大幅跑赢同期业绩比较基准收益率（24.74%）。 这其中，工银医药健康股票、工银健康生活混合、工银健康产业混合均为谭冬寒管理的基金；工银新经济混合目前由赵蓓管理。 这两位基金经理正是工银瑞信医药团队的核心成员，赵蓓2010年就已加入工银瑞信基金，2014年工银瑞信首只医药主题基金----工银医疗保健股票就是由 她执掌至今，成立近11年。 谭冬寒拥有临床医学博士学位，2013年加入工银瑞信基金，2016年开始参与管理基金产品。他管理时间最长的基金就是工银医药健 ...

Market Overview - The A-share market showed a strong performance on November 3, with a total of 3,535 stocks rising, led by cyclical stocks such as coal [1][4] - The market is experiencing a "high-low switch" in capital allocation, indicating that funds are not leaving the market but are instead seeking new opportunities [1][8] - The trading volume decreased to 2.13 trillion yuan, down from 2.35 trillion yuan on the previous trading day, indicating a slight decline in market activity [2] Sector Performance - The media sector continued to lead gains, with several stocks hitting the daily limit, including Sanqi Interactive Entertainment and Jishi Media [6][7] - Cyclical stocks, particularly in coal and oil, saw approximately 3% increases, while sectors like gold, semiconductors, and medical services experienced declines [4][15] - The banking and coal sectors are becoming preferred choices for defensive investments due to their high dividend yields [8] Stock Highlights - Yangguang Electric (300274) was notably active, rising over 5% to close at 199.47 yuan per share, with a trading volume exceeding 100 billion yuan [4][5] - Other stocks with significant gains included Zhaoyi Innovation (603986) and Industrial Fulian (601138), both rising over 4% [4] - The media sector stocks such as Sanqi Interactive Entertainment and Jishi Media saw substantial increases, with year-to-date gains of 53.57% and 117.65%, respectively [7] Investment Sentiment - Analysts suggest that the market may continue to exhibit index fluctuations and sector rotations, with a focus on structural opportunities [1][14] - The expectation of policy support and economic data resilience is driving market sentiment, with a shift from growth to value investing [8][15] - Investment strategies should focus on sectors with high growth potential, such as AI, robotics, and innovative pharmaceuticals, while avoiding overvalued themes [17]

Core Insights - The Chinese stock market has entered a phase of differentiation following significant meetings and US-China tariff negotiations, with the innovative drug sector showing strong performance [1] - The Hong Kong innovative drug ETF (513120) has seen a year-to-date increase of 91.72%, focusing on high-quality biotech companies in the Hong Kong market [3] - After a strong performance in the first three quarters of the year, the innovative drug sector experienced a brief adjustment but is now regaining upward momentum due to a series of favorable developments [4] Group 1: Major Positive Developments - The annual pharmaceutical procurement has sparked renewed interest in the pharmaceutical and biotech sectors, with negotiations for the 2025 national drug catalog starting on October 30 [5] - This adjustment marks the first inclusion of a "commercial health insurance innovative drug catalog," transitioning from a "basic insurance only" model to a collaborative payment system involving both insurance types [6] - A total of 535 drugs passed the formal review, with 310 generic names seeing a 24.5% increase compared to 2024, indicating a significant rise in interest and potential market expansion [5][6] Group 2: Market Dynamics and Financial Implications - The commercial insurance innovative drug catalog aims to address high-value innovative drugs that basic insurance cannot cover, thus creating a new revenue stream for pharmaceutical companies [6][7] - Predictions suggest that the payment scale for innovative drugs through commercial insurance will rise from 124 billion yuan in 2024 to 440 billion yuan by 2035, a 35-fold increase [7][8] - The innovative drug sector has seen substantial foreign licensing deals, with over $100 billion in total licensing agreements in the first ten months of 2025, surpassing the total for 2024 [13][16] Group 3: Company Performance and Growth - Companies like Innovent Biologics reported a third-quarter revenue exceeding 3.3 billion yuan, reflecting a robust 40% year-on-year growth, driven by strong sales of key products [17] - Other companies, such as Kelun Pharmaceutical and Junshi Biosciences, also reported significant revenue growth, with Kelun's new business segments seeing a 71.87% increase [18] - The overall innovative drug sector is expected to continue its growth trajectory, with an increase in approved innovative drugs and a potential turnaround in profitability by 2026 [18][19] Group 4: Investment Trends - Institutional interest in the biotech innovative drug sector remains high, with a 27.53% share of total holdings in the pharmaceutical industry, reflecting a 2.61 percentage point increase [19] - The Hong Kong innovative drug ETF (513120) has attracted over 10 billion yuan in net inflows in the past ten days, with a total net inflow of over 92.18 billion yuan year-to-date [19][20] - The recent adjustments in the innovative drug sector have led to renewed investment interest, as funds are confident in the sector's future growth potential [21][22]

Report Summary 1. Report Industry Investment Rating No industry investment rating information is provided in the report. 2. Core Viewpoints - A shares are likely to maintain high - level fluctuations, and the bond market and gold will experience short - term volatility. The report suggests paying attention to investment opportunities in directions such as computing power, chips, artificial intelligence, batteries, rare earths, and innovative drugs [13]. - The high risk preference is unfavorable to the bond market, but the high absolute yield makes it have long - term allocation value. The gold price may fluctuate in the short term, but the long - term upward trend remains unchanged [14]. 3. Summary According to Related Content Stock Market - **US Stocks and Hong Kong Stocks**: In the past week (20251027 - 20251102), the Nasdaq, S&P 500, and Dow Jones Industrial Average rose by 2.24%, 0.71%, and 0.75% respectively, while the Nasdaq China Technology Index fell by 1.00%. The Hang Seng Index fell by 0.97% [3]. - **A Shares**: The wind all - A index rose by 0.41%. Among them, the CSI A100 and CSI 300 fell by 0.51% and 0.43% respectively, while the CSI 500, CSI 1000, CSI 2000, and wind micro - cap stocks rose by 1.00%, 1.18%, 0.95%, and 0.34% respectively. In terms of sectors, the Shanghai blue - chip and growth sectors fell, the Shenzhen blue - chip sector fell while the growth sector rose, and the North Securities 50 index rose by 7.52%. Among the 30 CITIC industries, 21 industries rose, with the leading industries being basic chemicals, electric power and new energy, and comprehensive finance, with a weekly increase of more than 3.0%. Semiconductor, battery, photovoltaic, and other ETFs led the gains, with a weekly increase of more than 5% [4]. Bond Market - **Domestic Bonds**: In the past week, the price of treasury bond futures rose, and the yields of treasury bonds of all maturities decreased. The 10 - year treasury bond futures contract rose by 0.62%, and the yield of the 10 - year active treasury bond decreased by 5.32 BP to 1.7954%. The central bank's open - market operations had a net investment of 12008 billion yuan. The bond market leverage level decreased, and the 5 - day average of inter - bank pledged repurchase volume decreased from 7.83 trillion yuan on October 24, 2025, to 6.71 trillion yuan on October 31, 2025 [5][7]. - **US Bonds**: In the past week, US bond yields increased, and the yield curve shifted upward as a whole. As of October 31, 2025, the 10 - year US bond yield increased by 9 BP to 4.11% [8]. Foreign Exchange Market - The US dollar appreciated, and the US dollar index rose by 0.80%. The US dollar appreciated against the euro, pound, and yen. The US dollar exchange rate against the offshore and onshore RMB slightly decreased [9]. Gold Market - Gold prices continued to fall. The London spot gold price fell by 2.26% to $4011.50 per ounce, and the COMEX gold futures price fell by 3.08% to $3995.70 per ounce. The domestic gold price also continued to fall, with the Shanghai spot gold falling by 1.51% to 921.50 yuan per gram and the futures falling by 1.65% to 920.48 yuan per gram [10]. Policy and Event Impact - The central bank's resumption of treasury bond trading does not necessarily mean an increase in liquidity injection. It is only a liquidity management tool, and only an increase in net treasury bond purchases represents an increase in liquidity injection [11]. - The meeting between Chinese and US leaders in South Korea eased the economic and trade relations between the two countries, which is conducive to improving investors' risk preference [12].

Core Insights - The Chinese stock market is experiencing a divergence, with the innovative drug sector showing strong performance following significant meetings and US-China tariff negotiations [1] - The Hong Kong innovative drug ETF (513120) has seen a year-to-date increase of 91.72%, focusing on high-quality biotech companies in the innovative drug, gene therapy, and cutting-edge biotechnology sectors [3] Group 1: Policy and Market Developments - The annual pharmaceutical procurement has sparked renewed interest in the pharmaceutical and biotech sectors, with negotiations for the 2025 National Drug Directory adjustments taking place from October 30 to November 2 [4] - This adjustment marks the eighth since the establishment of the National Medical Insurance Administration, introducing a commercial health insurance innovative drug directory, which represents a shift from a single basic insurance model to a collaborative payment model involving both insurance types [5] - A total of 535 drugs passed the formal review, with 310 generic names seeing a 24.5% increase compared to 2024, indicating a record high for submissions [4][5] Group 2: Financial Implications for Companies - The commercial insurance innovative drug directory allows pharmaceutical companies to apply for both basic insurance and commercial insurance, potentially opening up significant revenue streams for high-value innovative drugs [5][6] - For instance, the drug Masitide from Innovent Biologics, which is a high-priced prescription drug not included in basic insurance, could generate tens of billions in revenue if included in the commercial insurance directory [6] - The projected payment scale for commercial insurance for innovative drugs is expected to rise from 12.4 billion yuan in 2024 to 440 billion yuan by 2035, a 35-fold increase [6] Group 3: Company Performance and Market Sentiment - The innovative drug sector has seen a surge in business development (BD) collaborations, with over $100 billion in total licensing agreements in the first ten months of 2025, surpassing the total for 2024 [12][15] - Notable collaborations include a $12 billion upfront payment deal between Innovent Biologics and Takeda, and a $16.4 billion deal between Prigen and Kite Pharma [15] - Recent quarterly reports from companies like Innovent Biologics and Kelun Biotech show strong revenue growth, with Innovent reporting over 3.3 billion yuan in Q3 2025, a 40% year-on-year increase [16][17] Group 4: Investment Trends - The innovative drug ETF (513120) has attracted over 10 billion yuan in net inflows in the last ten days, with a total of 92.18 billion yuan year-to-date, indicating strong institutional interest [18] - The ETF's focus on high-quality biotech companies, with a weight of 88.9% in innovative drugs and chemical pharmaceuticals, positions it as a leading investment vehicle in the sector [23][24] - The market sentiment remains optimistic, with funds re-entering the sector during price corrections, reflecting confidence in the industry's future growth potential [19][20]

Group 1 - The overall outlook for the Hong Kong stock market remains cautious but optimistic, with a focus on sectors benefiting from policy support such as new energy, innovative pharmaceuticals, and AI technology [3][6] - The market experienced significant fluctuations in October, with the Hang Seng Index reaching a peak on October 2 before declining due to concerns over US-China trade tensions, ultimately closing below 26,000 points [4][13] - The macroeconomic environment shows a weakening fundamental backdrop, with domestic economic data indicating a continued bottoming phase, while policy focus is on technological innovation and expanding domestic demand [5][31] Group 2 - In October, the valuation levels of the Hong Kong stock market decreased, with the Hang Seng Index's PE ratio dropping from 13.18 to 12.76, indicating a market valuation above the five-year average [19][20] - Southbound capital inflows showed a significant decrease in October, with net purchases amounting to 92.5 billion HKD, although the overall trend remains positive, providing liquidity support to the market [25][30] - The performance of various sectors in October was mixed, with defensive sectors like energy and utilities rebounding while previously strong sectors like technology and pharmaceuticals faced corrections [14][19] Group 3 - The domestic economic outlook is closely tied to the performance of the Hong Kong stock market, with the majority of earnings coming from Chinese companies, highlighting the importance of monitoring China's economic indicators [31] - Key economic data for September showed a GDP growth of 4.8%, with retail sales growth slowing to 3.0%, indicating weakening consumer demand [32][33] - Investment in fixed assets continued to decline, with a year-on-year drop of 7.1% in September, primarily driven by a significant decrease in real estate investment [36][44] Group 4 - The "14th Five-Year Plan" emphasizes technological innovation and industrial upgrading, aiming to enhance domestic demand and improve the consumption environment [64] - The Federal Reserve's recent interest rate cut and cautious stance on future rate adjustments are critical factors influencing the Hong Kong market, as external economic conditions remain uncertain [65][66] - The overall economic environment in the US shows moderate expansion, but uncertainties persist, particularly regarding inflation and employment data, which could impact market sentiment [67][68]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Views - The investment logic in the pharmaceutical sector is shifting from policy pressure to innovation-driven growth, with the "14th Five-Year Plan" directly supporting the development of innovative drugs and medical devices [8][26] - The industry is witnessing a transition from rapid following to original innovation, as demonstrated by Chinese companies showcasing their global competitiveness and pipeline value at the 2025 ESMO conference [8][26] - The recent approval of innovative drugs and the successful listing of companies on the STAR Market indicate a supportive capital market for innovative pharmaceutical enterprises [8][26] Industry Review - The pharmaceutical and biotechnology industry index increased by 1.89%, ranking 20th among 31 primary industries, underperforming the CSI 300 index which rose by 2.80% [5][16] - The sub-industries of medical research outsourcing and vaccines showed the highest gains, with increases of 5.26% and 4.19% respectively, while medical devices and traditional Chinese medicine experienced declines of 1.21% and 0.56% [5][16] - As of October 31, 2025, the industry’s PE (TTM, excluding negative values) was 30.67x, up from 30.08x in the previous period, indicating an upward valuation trend but still below the average [21] Company Dynamics - A total of 36 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 805 million yuan, with 4 companies increasing holdings by 120 million yuan and 32 companies reducing holdings by 925 million yuan [5][6] - Among the 501 tracked companies, 499 have disclosed their performance for the first three quarters of 2025, with 53 companies reporting a net profit growth of 100% or more, and 69 companies reporting growth between 30% and 100% [6] Investment Recommendations - Focus on companies with strong positions in innovative drugs and cutting-edge technology platforms, particularly those involved in ADC, bispecific/multispecific antibodies, and cell therapy, which can provide high potential for international market expansion [8] - Pay attention to the CXO industry, which is expected to see increased demand due to the recovery of innovative drug development and commercialization, especially for leading companies with strong service capabilities in new technology areas [8]